Neovasc is in the pre-clinical stage of developing the Tiara, a novel transcatheter device that will enable the treatment of mitral regurgitation, a condition that is often severe and can lead to heart failure and death. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated. There are approximately four million patients suffering with significant mitral regurgitation in the U.S.
The Tiara device is delivered through the apex of the heart or trans-venously to restore normal function of the mitral valve while preserving the integrity of the surrounding structures of the heart. Due to the complexity of the mitral valve anatomy, development of transcatheter treatments for mitral regurgitation has significantly lacked in comparison to aortic valve replacement devices.
